These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7237395)

  • 21. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
    Myers SE; Mick R; Williams SF
    Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
    Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
    J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine.
    Bezwoda WR; de Moor NG; Derman D; Lange M; Saner R; Dando R
    Cancer; 1979 Aug; 44(2):392-7. PubMed ID: 383254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
    Kopp HG; Krauss K; Fehm T; Staebler A; Zahm J; Vogel W; Kanz L; Mayer F
    Anticancer Res; 2011 Nov; 31(11):4025-30. PubMed ID: 22110237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
    Hortobagyi GN; Yap HY; Blumenschein GR; Gutterman JU; Buzdar AU; Tashima CK; Hersh EM
    Cancer Treat Rep; 1978 Nov; 62(11):1685-92. PubMed ID: 728894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.
    Passos-Coelho J; Ross AA; Davis JM; Huelskamp AM; Clarke B; Noga SJ; Davidson NE; Kennedy MJ
    Cancer Res; 1994 May; 54(9):2366-71. PubMed ID: 8162582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors.
    Smith RE
    J Natl Compr Canc Netw; 2006 Aug; 4(7):649-58. PubMed ID: 16884668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
    Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J
    J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
    Hortobagyi GN; Yap HY; Wiseman CL; Blumenschein GR; Buzdar AU; Legha SS; Gutterman JU; Hersh EM; Bodey GP
    Cancer Treat Rep; 1980 Jan; 64(1):157-9. PubMed ID: 6991103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
    Bezwoda WR; Seymour L; Dansey RD
    J Clin Oncol; 1995 Oct; 13(10):2483-9. PubMed ID: 7595697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
    Eder JP; Antman K; Peters W; Henner WD; Elias A; Shea T; Schryber S; Andersen J; Come S; Schnipper L
    J Clin Oncol; 1986 Nov; 4(11):1592-7. PubMed ID: 3534155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.